Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
Novavax, Inc (NASDAQ: NVAX) closed the day trading at $7.52 down -4.08% from the previous closing price of $7.84. In other words, the price has decreased by -$4.08 from its previous closing price. On the day, 8.06 million shares were traded. NVAX stock price reached its highest trading level at $7.85 during the session, while it also had its lowest trading level at $7.44.
Ratios:
For a better understanding of NVAX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.34 and its Current Ratio is at 2.36. In the meantime, Its Debt-to-Equity ratio is 6.07 whereas as Long-Term Debt/Eq ratio is at 5.93.
On June 17, 2025, Citigroup started tracking the stock assigning a Sell rating and target price of $6. On February 28, 2025, BTIG Research started tracking the stock assigning a Buy rating and target price of $19.BTIG Research initiated its Buy rating on February 28, 2025, with a $19 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 19 ’25 when YOUNG JAMES F bought 10,000 shares for $7.59 per share.
YOUNG JAMES F bought 4,000 shares of NVAX for $24,406 on Apr 14 ’25. On Dec 13 ’24, another insider, King Rachel K., who serves as the Director of the company, sold 4,150 shares for $9.02 each. As a result, the insider received 37,435 and left with 14,770 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NVAX now has a Market Capitalization of 1221413376 and an Enterprise Value of 837596800. As of this moment, Novavax,’s Price-to-Earnings (P/E) ratio for their current fiscal year is 3.33. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.09. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.13 while its Price-to-Book (P/B) ratio in mrq is 32.41. Its current Enterprise Value per Revenue stands at 0.776 whereas that against EBITDA is 2.055.
Stock Price History:
The Beta on a monthly basis for NVAX is 2.69, which has changed by -0.3255605 over the last 52 weeks, in comparison to a change of 0.14460516 over the same period for the S&P500. Over the past 52 weeks, NVAX has reached a high of $15.22, while it has fallen to a 52-week low of $5.01. The 50-Day Moving Average of the stock is 2.60%, while the 200-Day Moving Average is calculated to be -2.02%.
Shares Statistics:
Over the past 3-months, NVAX traded about 6.53M shares per day on average, while over the past 10 days, NVAX traded about 8718690 shares per day. A total of 162.16M shares are outstanding, with a floating share count of 147.97M. Insiders hold about 8.90% of the company’s shares, while institutions hold 58.80% stake in the company. Shares short for NVAX as of 1753920000 were 42311894 with a Short Ratio of 6.48, compared to 1751241600 on 46558353. Therefore, it implies a Short% of Shares Outstanding of 42311894 and a Short% of Float of 26.150000000000002.
Earnings Estimates
Investors are keenly observing as 3.0 analysts analyze and rate the current performance of Novavax, Inc (NVAX) in the stock market.The consensus estimate for the next quarter is -$0.55, with high estimates of $0.23 and low estimates of -$1.51.
Analysts are recommending an EPS of between $3.26 and $1.45 for the fiscal current year, implying an average EPS of $2.57. EPS for the following year is $0.12, with 6.0 analysts recommending between $2.9 and -$1.3.
Revenue Estimates
5 analysts predict $51.59M in revenue for the current quarter. It ranges from a high estimate of $89.8M to a low estimate of $32.55M. As of the current estimate, Novavax, Inc’s year-ago sales were $84.51MFor the next quarter, 5 analysts are estimating revenue of $141.49M. There is a high estimate of $264.9M for the next quarter, whereas the lowest estimate is $63.5M.
A total of 7 analysts have provided revenue estimates for NVAX’s current fiscal year. The highest revenue estimate was $1.21B, while the lowest revenue estimate was $1B, resulting in an average revenue estimate of $1.07B. In the same quarter a year ago, actual revenue was $682.16MBased on 7 analysts’ estimates, the company’s revenue will be $475.83M in the next fiscal year. The high estimate is $1.07B and the low estimate is $304.69M.
